Skip to main content
MapleLMS Implementation
Conferences and Meetings 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II

Short name: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II
Course start date: 11/05/2025

Sections

General
0 activities

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma
Association Between Dose Reduction and Duration of Therapy in Patients Receiving Ibrutinib or Acalabrutinib for Chronic Lymphocytic Leukemia: A Medical Chart Review Study
Barriers to Care Identified and Interventions Provided By Cancer Support Community’s Proactive CAR T Navigation Program: Bridging the Gap in Patient & Caregiver Needs
Clinical Outcomes and Patterns of Care Among Patients with Newly Diagnosed Hodgkin Lymphoma in a Safety-Net Health System
Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma
Disparities in Psychological Distress and Coping Behaviors Amongst Patients with Indolent Hematologic Malignancies
Duration of Therapy in Patients with Waldenstroem Macroglobulinemia Undergoing Dose Reductions of First-Line Ibrutinib: A Real-World Analysis
Economic Disparities Among Pediatric Acute Lymphoblastic Leukemia Readmissions in the United States: A Decade Trend Study
End-of-Life Care Patterns in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting
Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)
Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
Factors Influencing Clinical Trial Participation Among Patients with Non-Hodgkin Lymphoma Receiving Care in a Safety Net Hospital
Healthcare Resource Utilization and Costs in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Covalent Btki (cBTKi): Real-World Impact of Cardiovascular Adverse Events
Hospitalized Adults with Hematological Malignancies and RSV Infection: Paving the Way for Universal RSV Vaccination?
Household Poverty and Risk of Obesity during Maintenance Therapy for Childhood Acute Lymphoblastic Leukemia (ALL): Children’s Oncology Group (COG) Study AALL03N1 Report
Immune Checkpoint Inhibitors in Primary Mediastinal B-Cell Lymphoma: A Monocentric Real-Life Experience and Future Potential
Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM)
Impact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States
Incidence of Second Primary Malignancies in Hairy Cell Leukemia: US Population-Based Study from 2000- 2021
Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
Patient Characteristics and Treatment Patterns for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) By CAR T Eligibility and Treatment Status in France, Germany, Italy, Spain, the UK, and Japan
Perceptions of Clinical Trials and Factors Influencing Trial Participation Among Hispanic Patients with Non-Hodgkin Lymphoma
Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile
Real-World Clinical Outcomes in Patients Initiating Covalent Btki (cBTKi) with and without Incident Cardiovascular Adverse Events By Line of Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Real-World Predictors of Financial Toxicity in Patients with Lymphoma
Residential Economic and Racial Segregation Is Associated with Acuity and Severity of Pediatric Leukemia at Presentation
Symptoms Detection Among Patients with Lymphoid Malignancies (LM) Using Electronic Patient-Reported Outcomes (ePROs) in Community Hematology-Oncology Clinics
The Epidemiology of Hematologic Malignancies in East Asia from 1990 to 2021: Estimates from the Global Burden of Disease Study
The Impact of Lymphodepleting Chemotherapy Dose Modifications on Axicabtagene Ciloleucel Expansion and Treatment Outcome in Patients with Relapsed or Refractory CD19-Positive Diffuse Large B-Cell Lymphoma
The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma (NHL) - a Large, Multicenter Study
Treatment-Related Neuropathy Following Brentuximab-Vedotin in African Americans Treated for Lymphoma: A Retrospective Chart Review
Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study